DNA, D(P-THIO)((2'-O,4'-C-((S)-ETHYLIDENE))M5RC-(2'-O,4'-C-((S)-ETHYLIDENE))M5RC-(2'-O,4'-C-((S)-ETHYLIDENE))M5RC-G-A-T-A-G-M5C-T-G-G-T-(2'-O,4'-C-((S)-ETHYLIDENE))M5RU-(2'-O,4'-C-((S)-ETHYLIDENE))RG-(2'-O,4'-C-((S)-ETHYLIDENE))M5RU)
Cystic Fibrosis
Ionis Pharmaceuticals, Inc.nucleic_acidPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
82 Active assets in the Cystic Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tezacaftor Vertex Pharmaceuticals Incorporated | Phase 4 | A |
Lumacaftor Hospices Civils de Lyon | Phase 4 | BBB |
Liprotamase Anthera Pharmaceuticals | Phase 4 | BBB |
Ivacaftor Meyer Children's Hospital IRCCS | Phase 4 | BBB |
ELEXACAFTOR Meyer Children's Hospital IRCCS | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →